U.S. flag

An official website of the Department of Health & Human Services

AHRQ: Agency for Healthcare Research and Quality

Substance Use Tools & Resources   

Read the Guide

This collection of tools and resources is for providers, staff, and patients who offer or use services to address substance use, and other interested stakeholders. This collection was originally established following an environmental scan on implementing medication-assisted treatment (MAT) for opioid use disorder (OUD) in rural primary care. (See PDFs of Volume 1 (PDF - 609 KB) and Volume 2 (PDF - 1.3 MB) of that scan). Items have been continuously added to this collection since then, and the collection has expanded to cover substance use more broadly, rather than just MAT for OUD.

Displaying 241 - 250 of 992

Updated DEA Registration Certificate after Removal of X-Waiver (PDF - 92.4 KB)

This guidance document provides information regarding issuance of updated DEA registration certificates to reflect Congress’s elimination of the X-waiver (DATA-Waiver) in the Consolidated Appropriations Act of 2023, increasing accessibility of medication-assisted treatment (MAT).
Format
Fact Sheet/Brochure
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Drug Enforcement Administration (DEA)
Year
Resource Type
PDF

Variation Across States in Loss of Medicaid Coverage Among Pregnant Beneficiaries with Substance Use Disorders (PDF - 657 KB)

Using a national Medicaid claims database, this brief estimates the number of pregnant beneficiaries with substance use disorder who lost Medicaid coverage 60 days postpartum at the national and state-level.
Format
Report/Paper/Issue Brief
Audience
States
Policymakers and Payers
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Assistant Secretary for Planning and Evaluation (ASPE)
Year
Resource Type
PDF

Waiver Elimination (MAT Act)

This web page provides frequently asked questions regarding the 2023 Consolidated Appropriations Act, which eliminates the X-waiver (DATA-Waiver) and increases accessibility of medication-assisted treatment (MAT).
Format
Web Page
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Substance Abuse and Mental Health Services Administration (SAMHSA)
Year
Resource Type
Web Page

What are Opioids?

This fact sheet includes a basic description of opioids, a brief explanation of the risks, ways to prevent misuse, and strategies to helped loved ones who may be struggling with substance use disorder.
Format
Fact Sheet/Brochure
Audience
Patients
Families
Communities
Schools
Source
Partnership to End Addiction
Year
Resource Type
Web Page

What are Stimulants?

This fact sheet includes a basic description of stimulants, a brief explanation of the risks, ways to prevent misuse, and strategies to helped loved ones who may be struggling with substance use disorder.
Format
Fact Sheet/Brochure
Audience
Patients
Families
Communities
Schools
Source
Partnership to End Addiction
Year
Resource Type
Web Page

What is a DTx?

This page provides an overview on Digital therapeutics, which deliver patients evidence-based therapeutic interventions that are driven by high quality software programs to treat, manage, or prevent a disease or disorder. 
Format
Web Page
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Digital Therapeutics Alliance (DTA)
Year
Resource Type
Web Page

What is Fentanyl?

This fact sheet includes a basic description of fentanyl, a brief explanation of the danger, and strategies to helped loved ones who may be using or at risk of using fentanyl.
Format
Fact Sheet/Brochure
Audience
Patients
Families
Communities
Schools
Source
Partnership to End Addiction
Year
Resource Type
Web Page

Wound Care & Medical Triage for People Who Use Drugs and the Programs That Serve Them (PDF - 2.2 MB)

This comprehensive guide provides information and recommendations regarding general health, safer use practices, common viral, fungal, parasitic, and other injection-related infections, overdose and overamp, tapering, withdrawal, medications for opioid use disorder, and seeking medical care.

Format
Guide
Audience
Behavioral Health Providers
First Responders
Medical Providers
Other Team Members
Source
National Harm Reduction Technical Assistance Center (NASTAD)
Year
Resource Type
Web Page

Wounds, Withdrawal, and Overdose: What to Expect from Xylazine Drug Supply Adulteration

This 75-minute on-demand session from the ASAM 54th Annual Conference addresses the pharmacology, toxicology, diagnostic testing, and epidemiology of xylazine in exposures. The session includes didactic content, case-based narrative, review of literature, and panel discussion to review important topics about the emerging xylazine crisis in the US.
Format
Web-Based Course
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
American Society of Addiction Medicine (ASAM)
Year
Resource Type
Video